Phase 3 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to sign a consent form, understand what the study involves, and agree to follow all study procedures.
- You are between 18 and 75 years old (inclusive) on the date you sign the consent form, regardless of gender.
- You have been diagnosed with advanced liver cancer (hepatocellular carcinoma), either confirmed through a tissue or cell sample test, or diagnosed using recognised clinical guidelines.
- Your general health and ability to carry out daily activities is rated as good or mostly good (a score of 0 or 1 on a standard doctor-used scale).
- Your doctors expect you to live for at least 3 more months.
- You do not have serious problems with your blood, liver, kidneys, blood clotting, or heart function.
Who may not be able to join:
- You have previously been treated with certain specific medicines called camrelizumab or apatinib, or have received oncolytic virus therapy or other gene therapies.
- You have taken another experimental drug or used an experimental medical device within the past 4 weeks (or within 5 half-lives of that drug, whichever is the shorter period), or your immune system is significantly weakened.
- You have previously had your spleen removed.
- You are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Liang Peng, Third Affiliated Hospital, Sun Yat-Sen University
Phone: 020-85252621
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose-Limiting Toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.